• Skip to main content
  • Skip to primary sidebar

Experienced Indiana Law Firm | Trial Lawyers Giving Power to Your Voice for Over 55 Years

CohenMalad, LLP | Trial Lawyers Giving Power to Your Voice for Over 55 Years

CohenMalad is rated highly on Google Reviews by clients.
Toll Free866.446.7478Toll Free317.636.6481
Make a Payment free consult
  • English

Search

  • About Us
  • Attorneys
  • Services
    • Appellate Law
    • Business Services & Litigation
    • Class Action
    • Eminent Domain
    • Family Law
    • Medical Malpractice
    • Personal Injury
    • Pharmaceutical & Medical Device Litigation
    • Real Estate Services & Litigation
    • Sexual Abuse
  • Testimonials
  • Resources
    • Alerts
    • Firm News
    • Video Library
    • Blog
    • FAQs
  • Contact
  • English

Home » Intensive Statin Therapy May Increase Risk for Diabetes

Intensive Statin Therapy May Increase Risk for Diabetes

In 2011, the Journal of the American Medical Association (JAMA) published a study comparing the impact of intensive-dose and moderate-dose statin therapy and found an increased risk for the development of type 2 diabetes in patients treated with a higher dosage of the drugs.

Statin drugs such as Lipitor, Zocor, Crestor, and Pravachol are commonly used to treat patients with high low-density lipoprotein (LDL) cholesterol. Doctors prescribe these statin drugs along with diet and exercise to reduce the risk of cardiovascular events such as blood clots, blocked arteries, heart attack, and stroke for their patients.

Concern has been growing in the medical community regarding an association between the use of statin drugs and the development of type 2 diabetes. Multiple studies have been conducted using data from as many as thirteen different clinical trials (from 1996-2011) to determine the impact of statin drugs on patients. The study published by JAMA in 2011 was comprised of data from five specific statin trials and confirmed patients on intensive-dose statin drug treatment may have an increased risk for developing diabetes.

Shortly after JAMA released its study in 2011, the U.S. Food and Drug Administration (FDA) issued a safety communication and label change for all statin drugs warning doctors and patients of an increased risk for type 2 diabetes mellitus.
Recent studies have indicated that women taking Lipitor, or other statin drugs, have a higher risk for developing type 2 diabetes—especially those who have a body mass index under 25, which is considered a ‘normal’ weight range.

Our product liability attorneys are investigating claims of women who have been diagnosed with diabetes after taking Lipitor. If you or someone you care about has taken Lipitor and has been diagnosed diabetes, contact us. We have litigated thousands of product liability claims against pharmaceutical companies and medical device manufacturers and can help you obtain compensation for your injuries.

Primary Sidebar

ASK ABOUT AN INITIAL FREE CONSULTATION TODAY

  • Hidden
  • Hidden
  • This field is for validation purposes and should be left unchanged.

CohenMalad, LLP

One Indiana Square Suite 1400
Indianapolis, Indiana 46204
317.636.6481
Toll Free: 866.446.7478
  • twitter logo

Copyright © 2025 CohenMalad, LLP
Disclaimer Privacy Policy

  • About Us
  • Attorneys
  • Services
    ▼
    • Appellate Law
    • Business Services & Litigation
    • Class Action
    • Eminent Domain
    • Family Law
    • Medical Malpractice
    • Personal Injury
    • Pharmaceutical & Medical Device Litigation
    • Real Estate Services & Litigation
    • Sexual Abuse
  • Testimonials
  • Resources
    ▼
    • Alerts
    • Firm News
    • Video Library
    • Blog
    • FAQs
  • Contact
  • English
Cookies and other technology are used on this website to tailor your user experience and evaluate our marketing strategy. By clicking any link on this site you agree to our privacy policy.
En este sitio web utilizamos cookies y otras tecnologías para personalizar su experiencia de usuario y evaluar nuestra estrategia de marketing. Al hacer clic en cualquier enlace de esta plataforma, usted acepta nuestra política de privacidad.
Agree